10.3 Attention-Deficit/Hyperactivity Disorder (ADHD) & Pediatric Mood Disorders

10.3 Attention-Deficit/Hyperactivity Disorder (ADHD) & Pediatric Mood Disorders

Childhood and adolescent psychiatric disorders require a meticulous balance between developmental behavioral frameworks and targeted neurochemical pharmacotherapy. Clinicians must understand age-tiered treatment algorithms, delivery systems that mitigate misuse, adverse effect trajectories on growth and cardiovascular dynamics, and boxed warnings governing pediatric psychotropic use.

---

AAP ADHD Clinical Practice Guidelines: Diagnostic & Age-Tiered Management

Attention-Deficit/Hyperactivity Disorder (ADHD) is a neurodevelopmental disorder affecting 8% to 10% of school-aged children. Diagnosis is established according to DSM-5 criteria:

• Symptom Threshold: At least 6 symptoms of inattention and/or 6 symptoms of hyperactivity-impulsivity for children aged ≤ 16 years (at least 5 symptoms for adolescents aged ≥ 17 years).
• Duration & Chronicity: Symptoms must persist for at least 6 consecutive months to a degree that is inconsistent with the child's developmental level.
• Pervasiveness: Documented functional impairment across two or more settings (e.g., home, school, social relationships), verified using validated rating scales completed by multiple informants (e.g., Vanderbilt, Conners).
• Onset: Several inattentive or hyperactive-impulsive symptoms must have been present prior to 12 years of age.

AAP Age-Tiered ADHD Management Framework:

┌───────────────────────────────┬─────────────────────────────────────────────────────────────┐
│ Developmental Age Tier        │ Evidence-Based Clinical Practice Recommendation            │
├───────────────────────────────┼─────────────────────────────────────────────────────────────┤
│ Preschool                     │ • FIRST-LINE: Evidence-based Parent Training in Behavior   │
│ (Ages 4 - 5 years)            │   Management (PTBM) and/or classroom interventions.         │
│                               │ • SECOND-LINE: Methylphenidate ONLY if behavioral therapy   │
│                               │   fails and moderate-to-severe functional impairment remains│
├───────────────────────────────┼─────────────────────────────────────────────────────────────┤
│ Elementary / Middle School    │ • FIRST-LINE: FDA-approved medications (Stimulants have     │
│ (Ages 6 - 11 years)           │   greatest effect size ~1.0) PLUS behavioral interventions  │
│                               │ • School environment accommodations (IEP / 504 plan)        │
├───────────────────────────────┼─────────────────────────────────────────────────────────────┤
│ Adolescents                   │ • FIRST-LINE: FDA-approved medications with adolescent      │
│ (Ages 12 - 18 years)          │   assent, alongside behavioral therapy.                     │
│                               │ • Rigorous assessment for substance abuse & diversion risk. │
└───────────────────────────────┴─────────────────────────────────────────────────────────────┘

The Preschool Dilemma (Ages 4 to 5 Years)

In preschool children, behavioral interventions—specifically Parent Training in Behavior Management (PTBM) (e.g., Parent-Child Interaction Therapy [PCIT], Incredible Years, Triple P)—are strictly first-line. The landmark Preschool ADHD Treatment Study (PATS) demonstrated that while methylphenidate is efficacious in this age group, preschool children experience significantly higher rates of adverse effects (severe emotional lability, irritability, social withdrawal, weeping, and growth velocity deceleration) compared to older children. Pharmacotherapy (immediate-release methylphenidate starting at 2.5 mg BID, max 7.5 mg TID) is reserved exclusively for severe cases unresponsive to behavioral therapy.

---

Stimulant Pharmacotherapy: Mechanisms, Delivery Systems & Kinetics

Psychostimulants represent the most effective pharmacotherapy for ADHD, yielding a robust clinical effect size of approximately 1.0 (compared to 0.7 for non-stimulants).

Neurochemical Mechanism of Stimulant Classes:

Methylphenidate-Based Agents:              Amphetamine-Based Agents:
┌────────────────────────────────────┐     ┌────────────────────────────────────────────────────────┐
│ Blocks Dopamine Transporter (DAT)  │     │ 1. Blocks DAT and NET reuptake                         │
│ Blocks Norepinephrine Transp (NET) │     │ 2. Enters terminal via DAT ──► Reverses VMAT2          │
│                                    │     │ 3. Pushes DA & NE from vesicles into cytoplasm         │
│ Result: Increases synaptic DA & NE │     │ 4. Reverses DAT & NET ──► Massive active release       │
│ by preventing active reuptake.     │     │ Result: Reuptake blockade PLUS active catecholamine    │
│                                    │     │ release (Approximately 2x more potent than MPH).       │
└────────────────────────────────────┘     └────────────────────────────────────────────────────────┘

Formulation Technologies & Delivery Systems

Stimulant adherence and abuse mitigation are largely governed by formulation engineering:

1. Methylphenidate Formulations:
   • Immediate-Release (Ritalin, Methylin): Duration 3 to 5 hours. Requires twice- or thrice-daily dosing. Useful for initial dose titration or late-afternoon homework coverage.
   • OROS Delivery System (Concerta): Biphasic osmotic-release oral system lasting 10 to 12 hours. The tablet features an outer coating containing 22% of the dose for immediate release (Tmax ≈ 1 hour), while the semipermeable membrane encloses an osmotic push engine that absorbs water, expanding and steadily pushing the remaining 78% of the drug out of a laser-drilled orifice over 10 hours. Clinical Pearls: Must be swallowed whole; cannot be crushed, split, or chewed. Patients and parents must be counseled that the insoluble, non-absorbable shell ("ghost tablet") will appear intact in the stool and does not indicate therapeutic failure.
   • Dexmethylphenidate (Focalin, Focalin XR): Contains exclusively the pharmacologically active d-threo-enantiomer of methylphenidate (l-enantiomer is inactive). Administered at half the milligram dose of racemic methylphenidate. Focalin XR utilizes a 50:50 bimodal bead delivery system (SODAS) that can be opened and sprinkled onto applesauce.
   • Transdermal Methylphenidate (Daytrana Patch): Matrix transdermal system applied to the hip once daily. Worn for 9 hours to provide 11 to 12 hours of coverage; effects persist for 2 to 3 hours after patch removal. Avoid applying heat pads over patch (accelerates absorption). Risk of chemical leukoderma (permanent, irreversible loss of skin pigmentation).
2. Amphetamine Formulations:
   • Mixed Amphetamine Salts (Adderall IR, Adderall XR): Formulated as a 3:1 ratio of dextroamphetamine to levoamphetamine salts. Adderall XR contains 50% immediate-release beads and 50% delayed-release enteric-coated beads, providing 10 to 12 hours of therapeutic efficacy. Beads can be sprinkled on applesauce.
   • Lisdexamfetamine (Vyvanse): A therapeutically inactive prodrug consisting of d-amphetamine covalently bonded to the essential amino acid L-lysine.
     • Pharmacokinetic Bioactivation: After oral ingestion, the prodrug is rapidly absorbed across the intestinal epithelium via high-capacity peptide transporters (PEPT1). It undergoes zero enzymatic cleavage in the stomach or intestine. Bioactivation occurs via hydrolysis by aminopeptidases located on red blood cells (erythrocytes), releasing free active dextroamphetamine and L-lysine.
     • Abuse Deterrence: The rate of dextroamphetamine release is rate-limited by RBC enzymatic capacity and cannot be accelerated by chewing, crushing, snorting, or intravenous injection, markedly attenuating peak euphoric concentrations (Cmax) and lowering abuse liability.
     • Duration & Administration: Duration spans 10 to 14 hours. Capsule can be swallowed whole or opened and dissolved completely in water, orange juice, or yogurt.

Clinical Adverse Effects & Management

• Appetite Suppression & Weight Loss: The most common adverse effect (>50% of patients). Administer stimulants with or immediately after a high-calorie breakfast. Provide calorie-dense snacks in the late evening when stimulant concentrations decline. Monitor weight percentiles at every visit.
• Insomnia: Administer once-daily long-acting stimulants early in the morning (before 8:00 AM). If insomnia persists, shorten the duration of action (switch from 12-hour to 8-hour formulation) or add an evening dose of an alpha-2 adrenergic agonist (clonidine or guanfacine).
• Growth Deceleration: Long-term follow-up from the MTA study reveals a modest temporary reduction in growth velocity, resulting in an average adult height deficit of approximately 1 to 2 cm. Routine "drug holidays" (stopping medication on weekends and summer breaks) can be considered if significant growth failure occurs, provided behavioral symptoms do not cause severe social impairment.
• Motor / Vocal Tics: Stimulants do not cause primary tic disorders but may unmask or exacerbate pre-existing tics. If mild, continue stimulant therapy; if severe or distressing, switch to an alpha-2 agonist or atomoxetine.
• Cardiovascular Safety Screening:
  • Assess for a personal history of exertional syncope, chest pain, palpitations, or exercise intolerance.
  • Obtain a three-generation family history of sudden unexplained cardiac death before age 50, hypertrophic cardiomyopathy, long QT syndrome, or Wolff-Parkinson-White syndrome.
  • AAP / AHA Guidelines: A baseline routine screening electrocardiogram (ECG) is not universally mandated in healthy, asymptomatic children with a non-contributory cardiac history. Regularly monitor baseline and follow-up blood pressure and resting heart rate (expect average increases of 2 to 4 mmHg in BP and 3 to 6 bpm in heart rate).

---

Non-Stimulant ADHD Pharmacotherapy

Non-Stimulant ADHD Medication Profiles:

┌─────────────────┬───────────────────────────┬───────────────────────────────────────────┐
│ Drug Name       │ Mechanism of Action       │ High-Yield Clinical Pearls & Toxicities   │
├─────────────────┼───────────────────────────┼───────────────────────────────────────────┤
│ Atomoxetine     │ Selective Presynaptic NET │ • Weight-based dosing (0.5 to 1.2 mg/kg)  │
│ (Strattera)     │ Reuptake Inhibitor        │ • CYP2D6 substrate (5x higher in PMs)     │
│                 │                           │ • Boxed warning for suicidal ideation     │
│                 │                           │ • Rare idiosyncratic severe hepatotoxicity│
├─────────────────┼───────────────────────────┼───────────────────────────────────────────┤
│ Guanfacine ER   │ Postsynaptic Alpha-2A     │ • 1 to 4 mg once daily; less sedating     │
│ (Intuniv)       │ Adrenergic Receptor Agon. │ • Improves prefrontal executive function  │
│                 │                           │ • MUST TAPER: Rebound hypertension risk   │
├─────────────────┼───────────────────────────┼───────────────────────────────────────────┤
│ Clonidine ER    │ Non-selective Alpha-2     │ • 0.1 to 0.4 mg/day divided BID or QHS    │
│ (Kapvay)        │ Adrenergic Receptor Agon. │ • More sedating; beneficial for insomnia  │
│                 │                           │ • MUST TAPER: Severe rebound hypertension │
└─────────────────┴───────────────────────────┴───────────────────────────────────────────┘

Atomoxetine (Strattera)

• Mechanism: Highly selective presynaptic norepinephrine transporter (NET) inhibitor. Non-controlled substance with zero abuse potential.
• Dosing: Strictly weight-based dosing for patients ≤ 70 kg:
  • Initiate at 0.5 mg/kg/day orally for a minimum of 3 days.
  • Target maintenance dose: 1.2 mg/kg/day (maximum dose: 1.4 mg/kg/day or 100 mg/day, whichever is less), administered as a single daily morning dose or divided evenly morning and late afternoon.
• Pharmacokinetics & CYP2D6: Metabolized by CYP2D6 to active 4-hydroxyatomoxetine. In CYP2D6 poor metabolizers (~7% of Caucasians, 2% of African Americans), peak plasma concentrations are 5-fold higher, and the elimination half-life extends from 5 hours to 24 hours. When co-administered with strong CYP2D6 inhibitors (fluoxetine, paroxetine), do not exceed 0.5 mg/kg/day or 80 mg/day.
• Onset of Effect: Unlike stimulants which exert clinical effects on day 1, atomoxetine requires 2 to 4 weeks (up to 6 to 8 weeks) of continuous therapy for full clinical therapeutic response.
• Boxed Warning & Adverse Effects:
  • Boxed Warning: Increased risk of suicidal ideation in children and adolescents (pooled analysis: 0.4% in atomoxetine vs 0% in placebo).
  • Severe Liver Injury: Rare, severe idiosyncratic hepatotoxicity resulting in acute liver failure. Discontinue immediately in any patient developing jaundice, pruritus, or elevated transaminases; do not rechallenge.

Extended-Release Alpha-2 Adrenergic Agonists

• Guanfacine ER (Intuniv) & Clonidine ER (Kapvay): FDA-approved as monotherapy or adjunctive therapy to stimulants for ADHD in children aged 6 to 17 years. Highly effective when ADHD is accompanied by oppositional defiant disorder, tic disorders, severe emotional dysregulation, or stimulant-induced insomnia.
• Mechanism: Selectively stimulates postsynaptic alpha-2A adrenergic receptors in the prefrontal cortex, strengthening cortical network connectivity, enhancing working memory, and suppressing impulsive hyper-reactivity.
• Guanfacine vs. Clonidine: Guanfacine is 10 to 25 times more selective for the alpha-2A receptor subtype than clonidine (which non-selectively binds alpha-2A, alpha-2B, alpha-2C, and imidazoline receptors). Consequently, guanfacine produces significantly less sedation and less hypotension/bradycardia than clonidine.
• Dosing:
  • Guanfacine ER: Initiate at 1 mg once daily (morning or evening); titrate by 1 mg/day weekly to a target dose of 1 to 4 mg once daily (0.05 to 0.12 mg/kg/day).
  • Clonidine ER: Initiate at 0.1 mg at bedtime; titrate by 0.1 mg/day weekly up to 0.1 to 0.4 mg/day (administered BID).
• Critical Withdrawal Warning: Rebound Hypertension:

  [!CAUTION] Never abruptly discontinue extended-release alpha-2 agonists! Sudden cessation removes tonic central sympathetic outflow inhibition, provoking an acute surge in circulating catecholamines resulting in life-threatening rebound hypertension, reflex tachycardia, severe anxiety, and hypertensive encephalopathy. Regimens must be discontinued via a gradual downward taper (reduce guanfacine by no more than 1 mg every 3 to 7 days; reduce clonidine by no more than 0.1 mg every 3 to 7 days).

---

Pediatric Major Depressive Disorder (MDD) & Anxiety Disorders

Pharmacotherapy of pediatric mood and anxiety disorders is strictly governed by clinical trial evidence and FDA approval boundaries.

FDA-Approved SSRIs in Pediatric Mental Health:

┌─────────────────┬───────────────────────────────────────┬───────────────────────────────────┐
│ Drug Name       │ FDA-Approved Pediatric Indications    │ Minimum Approved Age              │
├─────────────────┼───────────────────────────────────────┼───────────────────────────────────┤
│ Fluoxetine      │ Major Depressive Disorder (MDD)       │ Approved down to age 8 years      │
│ (Prozac)        │ Obsessive-Compulsive Disorder (OCD)   │ Approved down to age 7 years      │
├─────────────────┼───────────────────────────────────────┼───────────────────────────────────┤
│ Escitalopram    │ Major Depressive Disorder (MDD)       │ Approved down to age 12 years     │
│ (Lexapro)       │                                       │                                   │
├─────────────────┼───────────────────────────────────────┼───────────────────────────────────┤
│ Sertraline      │ Obsessive-Compulsive Disorder (OCD)   │ Approved down to age 6 years      │
│ (Zoloft)        │ (Off-label for pediatric MDD)         │                                   │
├─────────────────┼───────────────────────────────────────┼───────────────────────────────────┤
│ Fluvoxamine     │ Obsessive-Compulsive Disorder (OCD)   │ Approved down to age 8 years      │
└─────────────────┴───────────────────────────────────────┴───────────────────────────────────┘

First-Line Agents for Pediatric MDD & Anxiety

• Selective Serotonin Reuptake Inhibitors (SSRIs): Function as the primary first-line pharmacotherapy when paired with Cognitive Behavioral Therapy (CBT) (supported by the landmark Treatment for Adolescents with Depression Study [TADS]).
• Fluoxetine (Prozac): The premier drug of choice. Highly effective for pediatric MDD and anxiety.
  • Pharmacokinetics: Fluoxetine and its active metabolite norfluoxetine possess an exceptionally long elimination half-life (fluoxetine half-life = 2 to 4 days; norfluoxetine half-life = 7 to 15 days). This unique pharmacokinetic profile creates a built-in "self-tapering" cushion that provides near-complete immunity against antidepressant discontinuation syndrome if an adolescent abruptly stops taking doses.
• Escitalopram (Lexapro): Second FDA-approved SSRI for pediatric MDD down to age 12. Displays minimal drug-drug interactions and zero anticholinergic properties.

The FDA Boxed Warning on Antidepressant-Induced Suicidality

In 2004, the FDA issued a Class Black Box Warning for all antidepressants regarding an increased risk of suicidal thoughts and behaviors in children, adolescents, and young adults (≤ 24 years of age):

• Epidemiological Risk: Comprehensive FDA meta-analyses of 24 trials involving >4,400 pediatric patients revealed an average risk of suicidal ideation and behaviors of 4% in antidepressant-treated patients versus 2% in placebo-treated patients (an absolute risk difference of 2 excess cases per 100 patients treated). Importantly, zero completed suicides occurred across all pediatric clinical trial datasets.
• Mandatory Clinical Monitoring Schedule: The FDA mandates a rigorous clinical monitoring protocol following initiation or dose escalation of any antidepressant in youth:
  • Weeks 1 to 4: Weekly contact (face-to-face or telephone)
  • Weeks 5 to 8: Biweekly contact (every 2 weeks)
  • Week 12: In-person clinical assessment, and periodically thereafter
• Caregiver Education: Counsel families to observe daily for the sudden emergence of agitation, severe anxiety, akathisia (motor restlessness), panic attacks, hypomania, insomnia, social withdrawal, or overt suicidal statements.

Serotonin Syndrome in Pediatrics

• Pathophysiology: Excess serotonin agonism at central and peripheral 5-HT1A and 5-HT2A receptors, commonly triggered by combining SSRIs with dextromethorphan, linezolid, tramadol, or triptans.
• Hunter Serotonin Toxicity Criteria: Presence of spontaneous clonus; inducible clonus with agitation or diaphoresis; ocular clonus with diaphoresis; or tremor and hyperreflexia with hyperthermia (>38°C).
• Distinguishing from Neuroleptic Malignant Syndrome (NMS): Serotonin syndrome is characterized by rapid onset (<24 hours), hyperreflexia, and spontaneous/inducible clonus, whereas NMS (induced by dopamine antagonists) exhibits subacute onset over days, "lead-pipe" muscle rigidity, hyporeflexia, and extreme hyperthermia.
• Treatment: Immediate discontinuation of serotonergic agents, supportive management (cooling, IV fluids, benzodiazepines for agitation), and oral/IV Cyproheptadine (5-HT2A antagonist: initial pediatric dose 0.25 mg/kg/day divided every 6 hours).

---

Practice Pearls & BCPPS Exam Traps

• Exam Trap 1: In a 4-year-old child presenting with severe hyperactivity and inattention, do not recommend initiating stimulant pharmacotherapy as the initial step; the AAP guidelines strictly require Parent Training in Behavior Management (PTBM) first.
• Exam Trap 2: A caregiver reports seeing an intact Concerta tablet in their 9-year-old child's stool and asks for a dose increase. Do not increase the dose; explain the OROS osmotic pump technology and reassure them that the drug was completely absorbed.
• Board Rule: When discontinuing extended-release guanfacine or clonidine, always provide a gradual titration schedule tapering by no more than 1 mg guanfacine (or 0.1 mg clonidine) every 3 to 7 days to prevent severe rebound hypertension.
• Exam Trap 3: Fluoxetine is FDA-approved for MDD down to age 8, whereas escitalopram is approved down to age 12; sertraline is FDA-approved for pediatric OCD down to age 6, but is NOT FDA-approved for pediatric MDD.